Physician profile
Khaleel Deeb
NPI 1053387761
$9,456.60
in general payments reported to CMS, 2019-2025
50 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $1,191 · 2021: $1,113 · 2022: $1,237 · 2023: $1,352 · 2024: $1,457 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,032.58 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,267.12 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,035.84 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $779.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $762.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $644.12 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $516.59 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $425.57 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Exact Sciences Corporation | $378.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $336.65 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $333.83 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $332.65 | 2019-2025 | Eliquis, Camzyos, Cobenfy |
| Pfizer INC. | $252.50 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $216.01 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amarin Pharma, INC. | $213.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $179.24 | 2019-2025 | Verquvo, Dificid, Capvaxive |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaleel Deeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.